Adili, R., Tourdot, B. E., Mast, K., Yeung, J., Freedman, J. C., Green, A., . . . Holinstat, M. (2017). First selective 12-LOX inhibitor, ML355, impairs thrombus formation and vessel occlusion in vivo with minimal effects on hemostasis. Arterioscler Thromb Vasc Biol.
Παραπομπή Chicago StyleAdili, Reheman, et al. "First Selective 12-LOX Inhibitor, ML355, Impairs Thrombus Formation and Vessel Occlusion in Vivo With Minimal Effects On Hemostasis." Arterioscler Thromb Vasc Biol 2017.
Παραπομπή MLAAdili, Reheman, et al. "First Selective 12-LOX Inhibitor, ML355, Impairs Thrombus Formation and Vessel Occlusion in Vivo With Minimal Effects On Hemostasis." Arterioscler Thromb Vasc Biol 2017.
Πρόσοχή: Οι παραπομπές μπορεί να μην είναι 100% ακριβείς.